SCYNEXIS (NASDAQ: SCYX) asks shareholders to approve 1-for-5–1-for-10 reverse split
SCYNEXIS, Inc. is asking shareholders at a virtual Special Meeting on May 19, 2026 to approve an amendment to its certificate of incorporation to permit a reverse stock split of its common stock at a ratio the Board may choose in the range 1-for-5 through 1-for-10. The Board would have discretion whether and when to implement the approved split and to abandon it despite shareholder approval.
The company states the board seeks flexibility to regain or maintain Nasdaq listing compliance and to reduce outstanding share counts; authorized common shares and outstanding shares would be reduced proportionately if the Board effects the split. The record date for voting is April 20, 2026, and proxy materials are available at www.proxyvote.com.
Positive
- None.
Negative
- None.
Insights
Proxy seeks shareholder approval for a board-authorized 1-for-5 to 1-for-10 reverse split to address Nasdaq compliance risks.
The proposal gives the Board post-approval discretion to select the split ratio and timing, and to abandon the split. This preserves flexibility so the Board can react to market conditions and anticipated trading price, but concentrates implementation authority with management.
Key dependencies include Nasdaq price behavior and the Board’s later judgment on ratio and timing; subsequent filings (including the Form 8-K with final vote results) will show whether the Board elects to implement the split and the chosen ratio.
The split would proportionately adjust outstanding stock awards and plan reserves; mechanics and rounding rules are specified.
The filing discloses that options, restricted stock units and performance RSUs (including exercise prices and share counts) will be adjusted proportionately at the Effective Time, with rounding down of shares and rounding up of exercise prices as described. Share-based limits under the Plans will be reduced proportionately.
Watch for the Board’s chosen ratio because it will determine post-split award counts and per-share exercise prices; timing and implementation details will be disclosed if the Board elects to effect the split.
Key Figures
Key Terms
Reverse Stock Split financial
Fractional shares financial
CUSIP market
Direct Registration System technical
recapitalization regulatory
TABLE OF CONTENTS
Filed by the Registrant ☒ | Filed by a party other than the Registrant ☐ | ||
☒ | Preliminary Proxy Statement |
☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
☐ | Definitive Proxy Statement |
☐ | Definitive Additional Materials |
☐ | Soliciting Material under §240.14a-12 |
☒ | No fee required |
☐ | Fee paid previously with preliminary materials |
☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
TABLE OF CONTENTS
1. | To approve an amendment to our Amended and Restated Certificate of Incorporation, to implement a reverse stock split of our common stock, at a ratio ranging from any whole number between 1-for-5 and 1-for-10, inclusive, with such ratio to be determined at the discretion of our Board of Directors, and decrease the number of authorized shares. |
TABLE OF CONTENTS
By Order of the Board of Directors | |||
Scott Sukenick Corporate Secretary and Chief Legal Officer Jersey City, New Jersey | |||
TABLE OF CONTENTS
Proposal No. | Proposal | Board Vote Recommendation | ||||
1 | Approval of an amendment to our Amended and Restated Certificate of Incorporation to implement a reverse stock split of our common stock, at a ratio ranging from any whole number between 1-for-5 and 1-for-10, inclusive, with such ratio to be determined at the discretion of our Board of Directors (the “Board”), and decrease the number of authorized shares (the “Reverse Stock Split Proposal”). | For | ||||
TABLE OF CONTENTS
Page | |||
QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING | 1 | ||
PROPOSAL 1 REVERSE STOCK SPLIT PROPOSAL | 7 | ||
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT | 17 | ||
HOUSEHOLDING OF PROXY MATERIALS | 19 | ||
OTHER MATTERS | 20 | ||
APPENDIX A | A-1 | ||
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | You may submit another properly completed proxy card with a later date. |
• | You may vote again by telephone or over the internet. |
• | You may send a timely written notice that you are revoking your proxy to our Corporate Secretary at SCYNEXIS, Inc., 1 Evertrust Plaza, 13th Floor, Jersey City, New Jersey 07302. |
• | You may attend the Special Meeting and vote at the Special Meeting. Simply attending the Special Meeting will not, by itself, revoke your proxy. |
TABLE OF CONTENTS
Proposal Number | Proposal Description | Vote Required for Approval | Effect of Abstentions | Effect of Broker Non-Votes | ||||||||
1 | Reverse Stock Split Proposal | “For” votes from the holders of a majority of votes cast by stockholders entitled to vote on the matter | No effect | Not applicable(1) | ||||||||
(1) | This proposal is considered to be a “routine” matter under the NYSE rules and therefore no broker non-votes are expected. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | To ensure continued ability to list our shares on The Nasdaq Capital Market. Our common stock is publicly traded and listed on The Nasdaq Capital Market under the symbol “SCYX.” The Nasdaq Capital Market has certain minimum price criteria applicable to securities traded on the exchange, including maintenance of a minimum closing bid price of $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2). On June 20, 2025, we received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that we had failed to comply with the minimum bid price requirement (the “Bid Price Requirement”). Following transfer from the Nasdaq Global Market to the Nasdaq Capital Market, we were provided until June 15, 2026 (the “Compliance Date”) to regain compliance with the Bid Price Requirement. If we fail to regain compliance with the Bid Price Requirement by the Compliance Date, Nasdaq may initiate delisting proceedings with respect to our common stock. Delisting from The Nasdaq Capital Market would have severe adverse consequences for the Company and its stockholders, including significantly reduced liquidity, diminished access to capital markets, and reputational harm. Our Board believes that effecting the Reverse Stock Split is the most direct and reliable means available to the Company to regain compliance with the Bid Price Requirement prior to the Compliance Date. Accordingly, the approval of the Reverse Stock Split Proposal at the Special Meeting is critical to the Company’s continued listing on The Nasdaq Capital Market. |
• | To potentially improve the marketability and liquidity of our common stock. Our Board believes that the increased market price of our common stock expected as a result of implementing a Reverse Stock Split could improve the marketability of our common stock, which could allow us to raise additional capital, in addition to improving the liquidity of our common stock and encouraging interest and trading in our common stock. |
• | Stock Price Requirements. Our Board believes that a higher stock price, which may be achieved through a Reverse Stock Split, could help facilitate the Company’s ability to raise new equity capital either through private fund-raising transactions or by accessing the equity capital markets, generally stimulate investor interest in the Company and help attract, retain, and motivate employees. |
• | Stock Price Volatility. Because of the trading volatility often associated with low-priced stocks, many brokerage houses and institutional investors have internal policies and practices that either prohibit them from investing in low-priced stocks or tend to discourage individual brokers from recommending low-priced stocks to their customers. Some of those policies and practices may make the processing of trades in low-priced stocks economically unattractive to brokers. |
• | Attract and Retain Employees. A higher market price per share for our common stock may help us attract and retain employees because some potential employees are less likely to work for a company with a low stock price, regardless of our market capitalization. |
• | Transaction Costs. Investors may be dissuaded from purchasing stocks below certain prices because brokers’ commissions, as a percentage of the total transaction value, can be higher for low-priced stocks. |
TABLE OF CONTENTS
• | our ability to maintain the listing of our common stock on The Nasdaq Capital Market; |
• | the historical trading price and trading volume of our common stock; |
• | the number of shares of our common stock outstanding immediately before and after the Reverse Stock Split; |
• | the then-prevailing trading price and trading volume of our common stock and the anticipated impact of the Reverse Stock Split on the trading price and trading volume of our common stock; |
• | the anticipated impact of a particular ratio on the number of holders of our common stock; and |
• | prevailing general market conditions. |
• | the market price per share of our common stock after the Reverse Stock Split will rise in proportion to the reduction in the number of shares of our common stock outstanding before the Reverse Stock Split; |
• | the Reverse Stock Split will facilitate our access to the equity capital markets; |
• | the Reverse Stock Split will result in a per share price that will increase the level of investment in our common stock by institutional investors or increase analyst and broker interest in us; |
• | the Reverse Stock Split will result in a per share price that will increase our ability to attract, retain and motivate employees and other service providers who receive compensation in the form of our equity-based securities; or |
• | the market price per share of our common stock will either exceed or remain in excess of the $1.00 minimum bid price as required by Nasdaq, or that we will otherwise meet the requirements of Nasdaq for continued inclusion for trading on The Nasdaq Capital Market. |
TABLE OF CONTENTS
TABLE OF CONTENTS
• | each 5 to 10 shares of our common stock owned by a stockholder (depending on the Reverse Stock Split ratio selected by our Board) will be combined into one new share of our common stock; |
• | no fractional shares of common stock will be issued in connection with the Reverse Stock Split; instead, holders of common stock who would otherwise receive a fractional share of common stock pursuant to the Reverse Stock Split will receive cash in lieu of the fractional share as explained more fully below under “Fractional Shares”; |
• | based upon the Reverse Stock Split ratio selected by our Board, proportionate adjustments will be made to the per share exercise price and the number of shares issuable upon the exercise or vesting of all then outstanding stock options, restricted stock units, performance restricted stock units and warrants (including the 43,500,000 shares of our common stock issuable upon exercise of the warrants issued pursuant to the Securities Purchase Agreement dated March 30, 2026, which are not reflected in the table set forth below), which will result in a proportional decrease in the number of shares of our common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock units, performance restricted stock units and warrants and, in the case of stock options and warrants, a proportional increase in the exercise price thereof; and the number of shares then reserved for issuance under the Plans will be reduced proportionately based upon the Reverse Stock Split ratio selected by our Board. |
Pre-Reverse Stock Split | Post-Reverse Stock Split (1-for-5) | Post-Reverse Stock Split (1-for-10) | |||||||
Authorized | 150,000,000 | 30,000,000 | 15,000,000 | ||||||
Outstanding | 79,442,633 | 15,888,526 | 7,944,263 | ||||||
Reserved for future issuance | 41,954,478 | 8,390,896 | 4,195,448 | ||||||
Authorized but unissued and unreserved | 28,602,670 | 5,720,579 | 2,860,290 | ||||||
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | banks, insurance companies, or other financial institutions; |
• | tax-exempt organizations, qualified retirement plans, individual retirement accounts or other tax deferred accounts, or governmental organizations; |
• | regulated investment companies or real estate investment trusts; |
• | S corporations, partnerships, or entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); |
• | brokers, dealers, or traders in securities; |
• | persons whose “functional currency” is not the U.S. dollar; |
• | persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment; |
• | persons who acquired our common stock in connection with employment or the performance of services; |
• | persons deemed to sell our common stock under the constructive sale provisions of the Code; |
• | “controlled foreign corporations,” “passive foreign investment companies,” or corporations that accumulate earnings to avoid U.S. federal income tax; |
• | persons subject to special tax accounting rules as a result of any item of gross income with respect to the common stock being taken into account in an applicable financial statement; or |
• | U.S. expatriates and former citizens or long-term residents of the United States. |
TABLE OF CONTENTS
• | an individual who is a citizen or resident of the United States; |
• | a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia; |
• | an estate, the income of which is subject to U.S. federal income tax regardless of its source; or |
• | a trust that (i) is subject to the primary supervision of a U.S. court and all substantial decisions of which are subject to the control of one or more “United States persons” (within the meaning of Section 7701(a)(30) of the Code) or (ii) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. |
• | the holder fails to furnish the holder’s taxpayer identification number, which for an individual is ordinarily his or her social security number; |
TABLE OF CONTENTS
• | the holder furnishes an incorrect taxpayer identification number; |
• | the applicable withholding agent is notified by the IRS that the holder previously failed to properly report payments of interest or dividends; or |
• | the holder fails to certify under penalties of perjury that the holder has furnished a correct taxpayer identification number and that the IRS has not notified the holder that the holder is subject to backup withholding. |
TABLE OF CONTENTS
• | each of our directors and named executive officers; |
• | all of our directors and executive officers as a group; and |
• | each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock. |
Name of Beneficial Owner | Number of Shares That Can be Acquired w/in 60 Days of April 1, 2026(1) | Number of Shares Beneficially Owned | Percentage Total | ||||||
5% Stockholders: | |||||||||
Avidity Partners Management LP(2) | 6,504,457 | 8,586,117 | 9.99% | ||||||
Entities affiliated with Great Point(3) | 424,366 | 7,978,713 | 9.99% | ||||||
Squadron Master Fund LP(4) | — | 7,608,695 | 9.58% | ||||||
Adage Capital Partners LP(5) | — | 4,347,826 | 5.47% | ||||||
Entities affiliated with Propel Bio Management, LLC(6) | — | 4,347,826 | 5.47% | ||||||
Named Executive Officers and Directors: | |||||||||
David Angulo, M.D. | 755,413 | 1,449,059 | 1.81% | ||||||
Ivor Macleod | 319,773 | 482,904 | * | ||||||
Scott Sukenick | 350,148 | 672,623 | * | ||||||
Armando Anido | 70,000 | 118,000 | * | ||||||
Steven C. Gilman, Ph.D. | 70,597 | 117,597 | * | ||||||
Ann F. Hanham, Ph.D. | 69,577 | 116,199 | * | ||||||
David Hastings | 69,577 | 115,760 | * | ||||||
Guy Macdonald | 82,645 | 137,645 | * | ||||||
Philippe Tinmouth | 65,500 | 116,500 | * | ||||||
All executive officers and directors as a group (9 persons)(7) | 1,853,230 | 3,326,287 | 4.09% | ||||||
* | Less than 1% of the outstanding shares of common stock. |
(1) | Reflects shares that may be acquired within 60 days of April 1, 2026, pursuant to the exercise of stock options or warrants. |
(2) | The amount reported as beneficially owned in the table is partially based on a Schedule 13G/A filed with the SEC on February 17, 2026, reporting beneficial ownership as of December 31, 2025. The amount in the table that may be acquired within 60 days of April 1, 2026 is based solely on information regarding warrants held by the entity that is known to us, and the actual amount may be different as the Schedule 13G/A does not delineate between shares held and shares that may be acquired within 60 days. The percentage of shares held assumes that the shares that may be acquired within 60 days is correct and is included in the total number of shares beneficially owned; accordingly, such percentage may actually be significantly higher. In addition to the foregoing, common warrants and pre-funded warrants to purchase an aggregate of 3,600,363 shares of common stock are excluded from the amount reported above as beneficially owned because they are subject to limitations on exercisability if such exercise would result in beneficial ownership of more than 9.99% of our outstanding shares of common stock. Each of Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital |
TABLE OF CONTENTS
(3) | The amount reported as beneficially owned in the table is partially based on a Schedule 13G filed with the SEC on April 7, 2026 by Great Point Partners, LLC reporting beneficial ownership of Biomedical Value Fund, L.P. as of March 31, 2026. The amount in the table that may be acquired within 60 days of April 1, 2026 is based solely on information regarding warrants held by the entity that is known to us, and the actual amount may be different than what is reported in the Schedule 13G. Consists of (i) 4,985,869 shares of common stock held by Biomedical Value Fund, L.P., (ii) 2,568,478 shares of common stock held by Biomedical Offshore Value Fund, Ltd, and (iii) 424,366 shares of common stock issuable upon exercise of pre-funded warrants held by Biomedical Value Fund, L.P. and Biomedical Offshore Value Fund, Ltd. In addition to the foregoing, pre-funded warrants to purchase an aggregate of 8,325,634 shares of common stock are excluded from the amount reported above as beneficially owned because they are subject to limitations on the exercisability if such exercise would result in beneficial ownership of more than 9.99% of our outstanding shares of common stock. Great Point Partners LLC serves as the investment manager of Biomedical Value Fund, L.P. Each of Jeffrey R. Jay and Lillian Nordahl, as managing members of Great Point Partners LLC, may be deemed to share voting and investment power over the shares held by Biomedical Value Fund, L.P. The principal business address for Biomedical Value Fund, L.P. is 165 Mason Street, 3rd Floor, Greenwich, Connecticut 06830. |
(4) | The amount reported as beneficially owned in the table is based solely on a Schedule 13G filed with the SEC on April 8, 2026, reporting beneficial ownership as of March 31, 2026. Squadron Capital Management, LLC, which serves as investment adviser to private funds, including but not limited to Squadron Master Fund LP (collectively, the “Funds”), may be deemed to be the beneficial owner of all shares held by the Funds. Matthew Sesterhenn and William Blank, as Partners of Squadron Capital Management, LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares held by the Funds. Squadron Capital Management, LLC and Mr. Sesterhenn and Mr. Blank expressly disclaim beneficial ownership over any of the securities. The principal business address for Squadron Master Fund LP is 999 Oakmont Plaza Drive, Suite 600, Westmont, Illinois 60559. |
(5) | Bob Atchinson and Phillip Gross are the managing members of Adage Capital Advisors, L.L.C., which is the managing member of Adage Capital Partners GP, L.L.C., which is the general partner of Adage Capital Partners LP, and each such person or entity, as the case may be, has shared voting and/or investment power over the securities held by Adage Capital Partners, LP and may be deemed the beneficial owner of such shares, and each such person or entity, as the case may be, disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. The principal business address for Adage Capital Partners LP is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. |
(6) | Consists of (i) 765,577 shares of common stock held by Propel Bio Partners L.P. and (ii) 3,582,249 shares of common stock held by Propel Bio-Host Partners L.P. (collectively, the “Propel Bio Funds”). Propel Bio Management LLC (“Propel”) and Leen Kawas (“Ms. Kawas”) provide advisory services to the Propel Bio Funds. Ms. Kawas is the sole owner of Propel. Propel and Ms. Kawas expressly disclaim beneficial ownership of the shares. Propel Bio Partners LLC (“General Partner”) serves as the general partner to a private investment fund managed by Propel. Ms. Kawas and Richard Kayne (“Mr. Kayne”) are control persons of the General Partner and each expressly disclaim beneficial ownership of the shares. The address for the entities and individuals is 340 Madison Avenue, 19th Floor, New York, NY 10173. |
(7) | Consists of shares held by each executive officer and director as of April 1, 2026, including the shares described in footnote (1) above. |
TABLE OF CONTENTS
TABLE OF CONTENTS
By Order of the Board of Directors | |||
Scott Sukenick | |||
Corporate Secretary and Chief Legal Officer | |||
TABLE OF CONTENTS
SCYNEXIS, Inc. | ||||||
By: | ||||||
David Angulo, M.D. | ||||||
Chief Executive Officer | ||||||
TABLE OF CONTENTS

TABLE OF CONTENTS
